Representative Carol Miller sold shares of Pfizer valued between $60,004 and $200,000. The transaction took place on March 10, 2025, according to a filing published on August 13, 2026.

At the time of reporting, Pfizer shares were trading at $26.61, down 0.69%.

Recent Trading Activity

Over the past three years, Miller executed 35 trades totaling over $238,000. Her largest trades involved Comcast and McKesson stock.

Regulatory Context

Under the STOCK Act signed into law in April 2012, members of Congress must file a Periodic Transaction Report within 30 days of notification and within 45 days of the transaction date. The act prohibits using private information for personal gain.

What the Numbers Show

The sale represents a significant portion of Miller’s recent trading activity. With 35 trades totaling $238,000 over three years, the Pfizer sale falls within the upper range of her disclosed transaction values, though specific per-trade averages are not provided in the source.

Pfizer delivered stronger-than-expected financial performance in its second quarter, reporting adjusted earnings per share (EPS) of $0.77 against an analyst consensus estimate of $0.69. The company’s quarterly sales reached $15.034 billion, exceeding the projected $14.412 billion and marking a modest growth trajectory compared to the prior year.

The results indicate that while top-line revenue growth remains moderate at 2.27% year-over-year, profitability metrics outperformed market expectations. The adjusted EPS beat of 11.59% suggests effective cost management or margin expansion despite the slight decline in absolute earnings compared to the previous year’s figure of $0.78 per share.

Financial Performance Overview

The key financial indicators for the quarter highlight a divergence between revenue growth and earnings power. While sales increased from $14.7 billion in the same period last year to $15.034 billion, the adjusted EPS decreased slightly by 1.28% from $0.78 to $0.77 on a year-over-year basis. However, the significant beat against analyst estimates underscores the company’s ability to generate value beyond initial market projections.

What the Numbers Show

The analytical observation from these figures is that Pfizer’s operational efficiency appears to be driving earnings quality more than volume growth. With sales rising only 2.27% year-over-year, the substantial 11.59% beat on EPS estimates implies that non-operational factors or disciplined expense control played a critical role in the quarter’s outcome. Investors should note that while the absolute EPS dipped slightly from last year’s $0.78, it significantly exceeded current market expectations, signaling resilience in the company’s core business model despite modest top-line expansion.